NSE · INDOUS
Indo Us Bio-Tech Ltd.
Revenue & net profit by period
Bars = revenue (₹ Cr) · line = net profit (₹ Cr). Straight from disclosed results.
Latest period: revenue ₹50 Cr with net profit ₹5 Cr — a 10.08% net margin, versus 12.2% the period before.
Shareholding
As of 2026-09-30
- Promoter68.29%
- Public31.45%
- FII0.01%
- DII0.25%
4,629 shareholders on record
Promoter holding trend
Each disclosed period, oldest to newest
52-week position
Where the current price sits in its yearly band
The band spans 2.77× from low to high.
Risk flags
Derived from disclosed data
- Under exchange surveillance — ST-ASM · ASM 1. Trading may carry price bands, periodic call auction or higher margins.
Peer comparison
Miscellaneous · ranked #225 of 552 by market cap · medians across 50 industry peers
| Company | Mkt cap | P/E | P/B | ROE | Margin |
|---|---|---|---|---|---|
| National Stock Exchange Of India Ltd. | ₹4,72,317 Cr | 42.76 | 11.29 | 26.24% | 62.66% |
| Adani Ports & Special Economic Zone Ltd. | ₹4,46,185 Cr | 32.27 | 4.36 | 13.33% | 31.98% |
| Eternal Limited | ₹3,50,452 Cr | 712.06 | 11.19 | 1.58% | 0.63% |
| BSE Limited | ₹1,54,996 Cr | 50.28 | 19.49 | 38.76% | 53.09% |
| Vedanta Aluminium Metal Limited | ₹1,47,050 Cr | 7.78 | 6.37 | 80.07% | 23.43% |
| GAIL (India) Ltd. | ₹1,22,159 Cr | 9.68 | 1.26 | 13.05% | 7.91% |
| One 97 Communications Ltd. | ₹1,15,268 Cr | 137.5 | 6.93 | 5.15% | 8.95% |
| Meesho Limited | ₹1,08,125 Cr | — | 25.7 | -21.93% | -6.19% |
| GMR Airports Limited | ₹1,05,277 Cr | 164.58 | 0 | -25.64% | 3.13% |
| Multi Commodity Exchange of India Ltd. | ₹89,961 Cr | 50.01 | 25.6 | 51.22% | 58.86% |
| Indo Us Bio-Tech Ltd.(this company) | ₹131 Cr | 30.25 | 1.46 | 4.72% | 4.48% |
AI analysis
AI-generated · google/gemini-2.5-flashIndo Us Bio-Tech Ltd. is listed on the Indian markets with a market capitalization of Rs 175 Cr. The company reported a revenue of Rs 104.02 Cr and an EPS of 8.11. The book value per share is Rs 39.16.
Positives
- +The promoter holding of 68.29% as of June 30, 2026, indicates a high level of confidence from the promoters.
- +The debt-to-equity ratio is low at 0.21.
- +Promoter pledges are 0% as of June 30, 2026, indicating no shares are used as collateral.
Negatives
- −Revenue decreased from Rs 30.85 Cr in Sept 2025 to Rs 22.80 Cr in Dec 2025.
- −Net profit decreased from Rs 4.7 Cr in Jun 2025 to Rs 1.97 Cr in Mar 2026.
- −No dividend yield information is available.
- −No revenue growth figures are provided for the latest annual period.
- −Profit margin information is not available.
Financial Performance
The company's revenue increased from Rs 40.15 Cr in Mar 2021 to Rs 50.24 Cr in Mar 2022. Net profit also rose from Rs 4.90 Cr in Mar 2021 to Rs 5.06 Cr in Mar 2022. The EPS grew from 8.07 in Mar 2021 to 8.27 in Mar 2022.
Profitability & Returns
Indo Us Bio-Tech Ltd. demonstrated a Return on Equity (ROE) of 23% and a Return on Capital Employed (ROCE) of 12.47%. The company's EPS is 8.11, while the PE ratio stands at 18.16.
Balance Sheet
The company has a debt-to-equity ratio of 0.21, indicating a limited reliance on debt financing. The book value per share is Rs 39.16.
Ownership & Pledges
As of June 30, 2026, promoters held 68.29% of the company's shares. Public shareholding was 31.70%, with FIIs holding a minor stake of 0.01%. There were no promoter share pledges reported.
Data as of — price: 2026-11-07 · financials: Mar 22 · shareholding: Sep 26. Figures are restated only when the company files again, so a period shown here is the most recent one on record — not necessarily the current quarter.
How this is produced: every figure above is computed from exchange filings and financial data mirrored by IPO Plus — no figure is generated or estimated. This is a factual summary for information and education only. It is not investment advice, not a recommendation to buy, sell or hold any security, and contains no price targets. Verify against the company's filings and the exchanges before any decision.